Feng Zhang (R) with Aera Therapeutics CEO Akin Akinc (Aera)

'Rare out­lier­s': Feng Zhang eyes a new path to ge­net­ic med­i­cine de­liv­ery with ex-Al­ny­lam lead­ers and $193M

Mar­quee CRISPR sci­en­tist Feng Zhang, two-decade Al­ny­lam on­col­o­gy head Akin Ak­inc and sea­soned biotech gu­ru John Maraganore have come to­geth­er for a new bet …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.